Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Angiodynamics (ANGO) EBT (2016 - 2025)

Angiodynamics (ANGO) has disclosed EBT for 16 consecutive years, with -$6.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT rose 41.42% year-over-year to -$6.4 million, compared with a TTM value of -$27.7 million through Nov 2025, up 88.33%, and an annual FY2025 reading of -$34.0 million, up 82.24% over the prior year.
  • EBT was -$6.4 million for Q4 2025 at Angiodynamics, up from -$10.8 million in the prior quarter.
  • Across five years, EBT topped out at $34.9 million in Q3 2023 and bottomed at -$199.7 million in Q1 2024.
  • Average EBT over 5 years is -$17.7 million, with a median of -$9.4 million recorded in 2022.
  • The sharpest move saw EBT soared 351.58% in 2023, then crashed 1966.85% in 2024.
  • Year by year, EBT stood at -$8.9 million in 2021, then decreased by 2.12% to -$9.1 million in 2022, then plummeted by 39.41% to -$12.6 million in 2023, then rose by 14.03% to -$10.8 million in 2024, then surged by 41.42% to -$6.4 million in 2025.
  • Business Quant data shows EBT for ANGO at -$6.4 million in Q4 2025, -$10.8 million in Q3 2025, and -$6.1 million in Q2 2025.